Mesentech

A group of pediatric rare diseases leave growing children at high risk of disuse-related fractures and breaks, via conditions such as Duchenne Muscular Dystrophy and Osteogenesis Imperfecta, also known as brittle bone disease. Existing therapies do not absorb well into bone, requiring high doses which lead to side effects and toxicity to the point where patients typically can not complete their therapy. Mesentech has developed a novel drug conjugate that avoids systemic exposure and side effects by specifically delivering the drug to bone tissues, allowing higher dosing with little to no side effects. Learn more.